866-997-4948(US-Canada Toll Free)

Kidney Cancer - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Jun 2015

Category :

Cancer

No. of Pages : 847 Pages

Kidney Cancer - Pipeline Review, H1 2015

Summary

Global Markets Directs, Kidney Cancer - Pipeline Review, H1 2015, provides an overview of the Kidney Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kidney Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Kidney Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Kidney Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Kidney Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Kidney Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 7
Kidney Cancer Overview 8
Therapeutics Development 9
Kidney Cancer - Therapeutics under Development by Companies 11
Kidney Cancer - Therapeutics under Investigation by Universities/Institutes 22
Kidney Cancer - Pipeline Products Glance 24
Kidney Cancer - Products under Development by Companies 28
Kidney Cancer - Products under Investigation by Universities/Institutes 41
Kidney Cancer - Companies Involved in Therapeutics Development 43
Kidney Cancer - Therapeutics Assessment 158
Drug Profiles 178
Kidney Cancer - Recent Pipeline Updates 561
Kidney Cancer - Dormant Projects 792
Kidney Cancer - Discontinued Products 810
Kidney Cancer - Product Development Milestones 814
Appendix 824

List of Tables
Number of Products under Development for Kidney Cancer, H1 2015 31
Number of Products under Development for Kidney Cancer - Comparative Analysis, H1 2015 32
Number of Products under Development by Companies, H1 2015 34
Number of Products under Development by Companies, H1 2015 (Contd..1) 35
Number of Products under Development by Companies, H1 2015 (Contd..2) 36
Number of Products under Development by Companies, H1 2015 (Contd..3) 37
Number of Products under Development by Companies, H1 2015 (Contd..4) 38
Number of Products under Development by Companies, H1 2015 (Contd..5) 39
Number of Products under Development by Companies, H1 2015 (Contd..6) 40
Number of Products under Development by Companies, H1 2015 (Contd..7) 41
Number of Products under Development by Companies, H1 2015 (Contd..8) 42
Number of Products under Development by Companies, H1 2015 (Contd..9) 43
Number of Products under Investigation by Universities/Institutes, H1 2015 45
Comparative Analysis by Late Stage Development, H1 2015 46
Comparative Analysis by Clinical Stage Development, H1 2015 47
Comparative Analysis by Early Stage Development, H1 2015 48
Comparative Analysis by Unknown Stage Development, H1 2015 49
Products under Development by Companies, H1 2015 50
Products under Development by Companies, H1 2015 (Contd..1) 51
Products under Development by Companies, H1 2015 (Contd..2) 52
Products under Development by Companies, H1 2015 (Contd..3) 53
Products under Development by Companies, H1 2015 (Contd..4) 54
Products under Development by Companies, H1 2015 (Contd..5) 55
Products under Development by Companies, H1 2015 (Contd..6) 56
Products under Development by Companies, H1 2015 (Contd..7) 57
Products under Development by Companies, H1 2015 (Contd..8) 58
Products under Development by Companies, H1 2015 (Contd..9) 59
Products under Development by Companies, H1 2015 (Contd..10) 60
Products under Development by Companies, H1 2015 (Contd..11) 61
Products under Development by Companies, H1 2015 (Contd..12) 62
Products under Investigation by Universities/Institutes, H1 2015 63
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 64
Kidney Cancer - Pipeline by Acceleron Pharma, Inc., H1 2015 65
Kidney Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2015 66
Kidney Cancer - Pipeline by Advaxis, Inc., H1 2015 67
Kidney Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015 68
Kidney Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2015 69
Kidney Cancer - Pipeline by Altor BioScience Corporation, H1 2015 70
Kidney Cancer - Pipeline by Ambrx, Inc., H1 2015 71
Kidney Cancer - Pipeline by Amgen Inc., H1 2015 72
Kidney Cancer - Pipeline by Amorfix Life Sciences Ltd., H1 2015 73
Kidney Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 74
Kidney Cancer - Pipeline by Angiogene Pharmaceuticals Limited, H1 2015 75
Kidney Cancer - Pipeline by APEIRON Biologics AG, H1 2015 76
Kidney Cancer - Pipeline by arGEN-X BV, H1 2015 77
Kidney Cancer - Pipeline by Argos Therapeutics, Inc., H1 2015 78
Kidney Cancer - Pipeline by ArQule, Inc., H1 2015 79
Kidney Cancer - Pipeline by Astellas Pharma Inc., H1 2015 80
Kidney Cancer - Pipeline by AstraZeneca Plc, H1 2015 81
Kidney Cancer - Pipeline by Aurigene Discovery Technologies Limited, H1 2015 82
Kidney Cancer - Pipeline by Bayer AG, H1 2015 83
Kidney Cancer - Pipeline by Beta Pharma, Inc., H1 2015 84
Kidney Cancer - Pipeline by BIND Therapeutics, Inc., H1 2015 85
Kidney Cancer - Pipeline by Bio-Cancer Treatment International Limited, H1 2015 86
Kidney Cancer - Pipeline by Biogenomics Limited, H1 2015 87
Kidney Cancer - Pipeline by Bionomics Limited, H1 2015 88
Kidney Cancer - Pipeline by BioNovion B.V., H1 2015 89
Kidney Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 90
Kidney Cancer - Pipeline by Boston Biomedical, Inc., H1 2015 91
Kidney Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015 92
Kidney Cancer - Pipeline by Caladrius Biosciences, Inc. , H1 2015 93
Kidney Cancer - Pipeline by Calithera Biosciences, Inc., H1 2015 94
Kidney Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2015 95
Kidney Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2015 96
Kidney Cancer - Pipeline by Celltrion, Inc., H1 2015 97
Kidney Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015 98
Kidney Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2015 99
Kidney Cancer - Pipeline by Conkwest, Inc., H1 2015 100
Kidney Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2015 101
Kidney Cancer - Pipeline by CureTech Ltd., H1 2015 102
Kidney Cancer - Pipeline by Cytune Pharma SAS, H1 2015 103
Kidney Cancer - Pipeline by Ecrins Therapeutics SAS, H1 2015 104
Kidney Cancer - Pipeline by Eisai Co., Ltd., H1 2015 105
Kidney Cancer - Pipeline by Eli Lilly and Company, H1 2015 106
Kidney Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 107
Kidney Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2015 108
Kidney Cancer - Pipeline by Exelixis, Inc., H1 2015 109
Kidney Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 110
Kidney Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2015 111
Kidney Cancer - Pipeline by GenSpera, Inc., H1 2015 112
Kidney Cancer - Pipeline by GlaxoSmithKline Plc, H1 2015 113
Kidney Cancer - Pipeline by Glycotope GmbH, H1 2015 114
Kidney Cancer - Pipeline by Hemispherx Biopharma, Inc., H1 2015 115
Kidney Cancer - Pipeline by Hospira, Inc., H1 2015 116
Kidney Cancer - Pipeline by Hutchison MediPharma Limited, H1 2015 117
Kidney Cancer - Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2015 118
Kidney Cancer - Pipeline by immatics biotechnologies GmbH, H1 2015 119
Kidney Cancer - Pipeline by Immune Design Corp., H1 2015 120
Kidney Cancer - Pipeline by Immunicum AB, H1 2015 121
Kidney Cancer - Pipeline by ImmunoGen, Inc., H1 2015 122
Kidney Cancer - Pipeline by Immunomedics, Inc., H1 2015 123
Kidney Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 124
Kidney Cancer - Pipeline by Incyte Corporation, H1 2015 125
Kidney Cancer - Pipeline by Innate Immunotherapeutics Limited, H1 2015 126
Kidney Cancer - Pipeline by InteRNA Technologies B.V., H1 2015 127
Kidney Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 128
Kidney Cancer - Pipeline by Johnson & Johnson, H1 2015 129
Kidney Cancer - Pipeline by KAHR medical Ltd., H1 2015 130
Kidney Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 131
Kidney Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 132
Kidney Cancer - Pipeline by Mabion SA, H1 2015 133
Kidney Cancer - Pipeline by MacroGenics, Inc., H1 2015 134
Kidney Cancer - Pipeline by MediaPharma s.r.l., H1 2015 135
Kidney Cancer - Pipeline by MediGene AG, H1 2015 136
Kidney Cancer - Pipeline by MedImmune, LLC, H1 2015 137
Kidney Cancer - Pipeline by Merck & Co., Inc., H1 2015 138
Kidney Cancer - Pipeline by Merck KGaA, H1 2015 139
Kidney Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 140
Kidney Cancer - Pipeline by Mirati Therapeutics Inc., H1 2015 141
Kidney Cancer - Pipeline by Mologen AG, H1 2015 142
Kidney Cancer - Pipeline by NewLink Genetics Corporation, H1 2015 143
Kidney Cancer - Pipeline by Novartis AG, H1 2015 144
Kidney Cancer - Pipeline by Omeros Corporation, H1 2015 145
Kidney Cancer - Pipeline by Oncobiologics, Inc., H1 2015 146
Kidney Cancer - Pipeline by Oncolys BioPharma Inc., H1 2015 147
Kidney Cancer - Pipeline by OncoMax, H1 2015 148
Kidney Cancer - Pipeline by Oncothyreon Inc., H1 2015 149
Kidney Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 150
Kidney Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 151
Kidney Cancer - Pipeline by Panacea Biotec Limited, H1 2015 152
Kidney Cancer - Pipeline by Panacela Labs, Inc., H1 2015 153
Kidney Cancer - Pipeline by Peloton Therapeutics, Inc., H1 2015 154
Kidney Cancer - Pipeline by Pfizer Inc., H1 2015 155
Kidney Cancer - Pipeline by Pharmicell Co., Ltd., H1 2015 156
Kidney Cancer - Pipeline by Pivotal BioSciences, Inc., H1 2015 157
Kidney Cancer - Pipeline by Plexxikon Inc., H1 2015 158
Kidney Cancer - Pipeline by Pono Pharma, H1 2015 159
Kidney Cancer - Pipeline by Prima BioMed Ltd., H1 2015 160
Kidney Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2015 161
Kidney Cancer - Pipeline by Qu Biologics Inc., H1 2015 162
Kidney Cancer - Pipeline by Recombio S.L, H1 2015 163
Kidney Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 164
Kidney Cancer - Pipeline by Sanofi, H1 2015 165
Kidney Cancer - Pipeline by Seattle Genetics, Inc., H1 2015 166
Kidney Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 167
Kidney Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2015 168
Kidney Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2015 169
Kidney Cancer - Pipeline by TC BioPharm Limited, H1 2015 170
Kidney Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 171
Kidney Cancer - Pipeline by Theravectys S.A., H1 2015 172
Kidney Cancer - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 173
Kidney Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 174
Kidney Cancer - Pipeline by TVAX Biomedical, Inc., H1 2015 175
Kidney Cancer - Pipeline by Vascular Biogenics Ltd., H1 2015 176
Kidney Cancer - Pipeline by Vaxeal Holding SA, H1 2015 177
Kidney Cancer - Pipeline by Welichem Biotech Inc., H1 2015 178
Kidney Cancer - Pipeline by Zymeworks Inc., H1 2015 179
Assessment by Monotherapy Products, H1 2015 180
Assessment by Combination Products, H1 2015 181
Number of Products by Stage and Target, H1 2015 183
Number of Products by Stage and Mechanism of Action, H1 2015 191
Number of Products by Stage and Route of Administration, H1 2015 197
Number of Products by Stage and Molecule Type, H1 2015 199
Kidney Cancer Therapeutics - Recent Pipeline Updates, H1 2015 583
Kidney Cancer - Dormant Projects, H1 2015 814
Kidney Cancer - Dormant Projects (Contd..1), H1 2015 815
Kidney Cancer - Dormant Projects (Contd..2), H1 2015 816
Kidney Cancer - Dormant Projects (Contd..3), H1 2015 817
Kidney Cancer - Dormant Projects (Contd..4), H1 2015 818
Kidney Cancer - Dormant Projects (Contd..5), H1 2015 819
Kidney Cancer - Dormant Projects (Contd..6), H1 2015 820
Kidney Cancer - Dormant Projects (Contd..7), H1 2015 821
Kidney Cancer - Dormant Projects (Contd..8), H1 2015 822
Kidney Cancer - Dormant Projects (Contd..9), H1 2015 823
Kidney Cancer - Dormant Projects (Contd..10), H1 2015 824
Kidney Cancer - Dormant Projects (Contd..11), H1 2015 825
Kidney Cancer - Dormant Projects (Contd..12), H1 2015 826
Kidney Cancer - Dormant Projects (Contd..13), H1 2015 827
Kidney Cancer - Dormant Projects (Contd..14), H1 2015 828
Kidney Cancer - Dormant Projects (Contd..15), H1 2015 829
Kidney Cancer - Dormant Projects (Contd..16), H1 2015 830
Kidney Cancer - Dormant Projects (Contd..17), H1 2015 831
Kidney Cancer - Discontinued Products, H1 2015 832
Kidney Cancer - Discontinued Products (Contd..1), H1 2015 833
Kidney Cancer - Discontinued Products (Contd..2), H1 2015 834
Kidney Cancer - Discontinued Products (Contd..3), H1 2015 835

List of Figures
Number of Products under Development for Kidney Cancer, H1 2015 31
Number of Products under Development for Kidney Cancer - Comparative Analysis, H1 2015 32
Number of Products under Development by Companies, H1 2015 33
Number of Products under Investigation by Universities/Institutes, H1 2015 44
Comparative Analysis by Clinical Stage Development, H1 2015 47
Comparative Analysis by Early Stage Products, H1 2015 48
Assessment by Monotherapy Products, H1 2015 180
Number of Products by Top 10 Targets, H1 2015 182
Number of Products by Stage and Top 10 Targets, H1 2015 182
Number of Products by Top 10 Mechanism of Actions, H1 2015 190
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 190
Number of Products by Top 10 Routes of Administration, H1 2015 196
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 196
Number of Products by Top 10 Molecule Types, H1 2015 198
Number of Products by Stage and Top 10 Molecule Types, H1 2015 198

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *